Cachexia is a major side effect of cancer, resulting in significant muscle wasting, fat loss and organ failure. Up to 80% of cancer patients suffer and 25% succumb to this condition. This significantly affects the treatment regimens of cancer patients and affects their quality of life. We have developed monoclonal antibodies that block and reverse cachexia in preclinical mouse cancer models. Our aims are to humanise the antibody and manufacture it for the first clinical trial in humans.
We have discovered a single tumour factor which causes cancer cachexia, a wasting condition that is one of the worst complications of malignancy, for which there is no current effective treatment. We have developed antibodies which effectively block this condition in preclinical models and have produced human/humanised version of this. This application is to characterise these human antibodies to allow us proceed to clinical trials.
From The Synchrotron To The Clinic: Translation Of A Novel Functional Lung Imaging Technology
Funder
National Health and Medical Research Council
Funding Amount
$891,834.00
Summary
Our team has recently developed a synchrotron technology with a startling capacity for dynamic functional imaging that can act as a sensitive regional indicator of lung disease. We will demonstrate that this technology can be translated from the synchrotron to the lab and eventually the clinic. We will provide proof of this concept by the application of this technology to emphysema, asthma, lung cancer, cystic fibrosis lung disease and neonatal resuscitation.